Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Scand J Immunol. 2022 Sep;96(3):e13197. doi: 10.1111/sji.13197. Epub 2022 Jun 30.
Despite the advances in the diagnosis and treatment of renal cell carcinoma (RCC), it remains one of the most deadly urological cancers. At present, using immune checkpoint inhibition and their combination with antiangiogenic therapy is the standard of care in patients with advanced RCC. Unfortunately, a considerable part of tumour-bearing hosts does not benefit from this type of treatment. However, our knowledge about the detailed role of mucin-domain containing-3 (TIM-3) in the RCC cells is little, and further studies are required in this field, but its significant expression in the RCC microenvironment makes this receptor a promising target for designing new monoclonal antibodies alone or in combination with other checkpoint inhibitors for RCC immunotherapy.
尽管在肾细胞癌 (RCC) 的诊断和治疗方面取得了进展，但它仍然是最致命的泌尿系统癌症之一。目前，在晚期 RCC 患者中，使用免疫检查点抑制及其与抗血管生成治疗的联合治疗是标准治疗方法。不幸的是，相当一部分肿瘤宿主不能从这种治疗中获益。然而，我们对黏蛋白结构域包含蛋白 3 (TIM-3) 在 RCC 细胞中的详细作用知之甚少，这一领域需要进一步研究，但它在 RCC 微环境中的显著表达使得该受体成为设计新的单克隆抗体的有前途的靶点，这些单克隆抗体可以单独使用或与其他检查点抑制剂联合用于 RCC 免疫治疗。
